Breaks Categories: Stock Spotlights

FridayApr 17, 2020 12:15 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Securities Purchase Agreement to Raise $3.5 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock (http://nnw.fm/r6SCU). An article discussing the company reads, “The company explained that it has entered into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance of up to 1,650,165 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 3,300,330 shares of common stock at $2.121 per share of common stock and…

Continue Reading

TuesdayApr 07, 2020 3:07 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Vaccine, Drug-Development Platform Targeting Coronaviruses, Acute Respiratory Syndromes

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced the launch of a new AI vaccine and drug development platform targeting coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS). An article discussing the company reads, “Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to…

Continue Reading

WednesdayFeb 26, 2020 12:21 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all…

Continue Reading

FridayFeb 14, 2020 2:26 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Names New Member to Board of Directors

Predictive Oncology (NASDAQ: POAI) recently announced the appointment of Pam Prior, CPA, to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. An article further discussing the company reads, “Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company…

Continue Reading

TuesdayJan 28, 2020 1:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, POAI can leverage two unique proprietary assets, from its acquisition of Helomics, which virtually eliminate development risk, a factor that considerably weighs on competitors’ efforts in the precision medicine space. First, Predictive Oncology possesses a clinically validated, tumor-profiling platform built from data derived from actual…

Continue Reading

FridayJan 17, 2020 3:32 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Aims to Commercialize AI-Driven Predictive Model of Ovarian Cancer in Q1 2020

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, recently issued an update regarding its groundbreaking CancerQuest 2020 initiative driven by its Helomics subsidiary (http://nnw.fm/y6fnc). Per the update, the company intends to have its first predictive model of ovarian cancer prepared for initial commercialization in the first quarter of 2020. An article discussing the company reads, “‘We believe that this effort will enhance our understanding of the molecular profiles of women with ovarian cancer by using the power of artificial intelligence to create predictive…

Continue Reading

TuesdayJun 11, 2019 12:33 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Advances Toward Lead Drug Candidate Commercialization through Retaining Addison Whitney to Oversee Naming Process

Genprex (NASDAQ: GNPX), a clinical-stage, gene-therapy company, recently announced that it has retained pharmaceutical branding agency Addison Whitney to assist with the naming of the company’s leading drug candidate (http://nnw.fm/4arQW). An article further discussing the company reads, “Addison Whitney has a proven track record of branding success within the pharmaceutical market. It enables clients to achieve growth through both brand differentiation and creative naming practices. Its most recent successes include guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps needed for name approval. . . . According to Genprex Chairman and CEO Rodney Varner, retaining the services…

Continue Reading

WednesdayJun 05, 2019 2:41 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Developing Gene Therapy-based Approach to Treat Non-small Cell Lung Cancer

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is developing Oncoprex immunogene therapy as an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (“NSCLC”). An article further discussing the company reads, “NSCLC is the most common type of lung cancer. It accounts for approximately 85% of all lung-cancer cases, and despite the development of innovative treatment strategies, the survival rate for lung cancer patients has not improved significantly over the past 25 years (http://nnw.fm/0YVIu) . . . . Breakthrough technologies and therapeutic approaches like those developed by Genprex could take cancer treatment solutions to a new level of…

Continue Reading

FridayMay 17, 2019 1:14 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, “Oncoprex is designed to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, to target and kill cancer cells via receptor pathways, and to stimulate natural immune responses against cancer. Oncoprex consists of the TUSC2 tumor suppressor gene encapsulated in a positively charged lipid nanoparticle. It is injected intravenously, specifically targeting cancer cells, which generally have a negative electrical charge.…

Continue Reading

ThursdayMay 02, 2019 3:14 pm

BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment study (http://nnw.fm/8E4bC). An article discussing the study reads, “The results of the study, which analyzed the combination of the TUSC2 gene and anti-PD1 antibody pembrolizumab, were presented in a poster at the 2019 American Association of Cancer Research Meeting. TUCS2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. . . . The poster data showed…

Continue Reading